, with the vision of creating new therapies to treat acute and intermittent medical conditions through a new and novel technology.
, was stimulated, in part, by studying early work on the "smokeless cigarette".
WASHINGTON, April 10 /PRNewswire/ -- The Chemical Heritage Foundation (CHF) and the Biotechnology Industry Organization (BIO) presented the 8th Annual Biotechnology Heritage Award to Alejandro Zaffaroni
, an outstanding pioneer of the biotechnology revolution and legendary entrepreneur with considerable scientific and business skills.
, Frazier Healthcare, Versant Ventures, 5AM Ventures, Burrill & Co.
Invitrogen is also sponsor of the Chemical Heritage Foundation and BIO's 8th Annual Biotechnology Heritage Award, which will be given to industry pioneer Alejandro Zaffaroni
, founder of several biotechnology companies and someone who truly exemplifies innovation.
Health Award for improving health in developing nations by creating sterile pre-filled, single-use syringes for vaccines, that are easy to administer and cannot be reused.
, renowned biotechnology pioneer and investor, founded Alexza.
Previous investors participating in the financing include Alejandro Zaffaroni
, Arch Venture Partners, CMEA Ventures, Frazier & Co.
The financing was led by the Sprout Group and co-led by Tavistock Life Sciences, and included CMEA Ventures, Lombard Odier & Cie, Novartis BioVenture Fund, Aravis Ventures, Alejandro Zaffaroni
, and the Singapore Economic Development Board, among others.
, who was also the founder of ALZA Corporation and others, with the aim of developing drugs that "provide treatment when needed, in the amount needed.
Among those Rosenkranz recruited from outside the country were Juan Pataki, a Hungarian trained in Switzerland by Ruzicka; Esteban Kaufmann, a longtime friend and colleague who also was trained by Ruzicka; Carl Djerassi, an Austrian refugee who at 26 year old Austrian who was acquiring professional fame through his prolific writings and research; and Alejandro Zaffaroni
, a Uruguayan who had earned an international reputation for his work demonstrating the applicability of paper chromatography to steroids.
Kalypsys completed a $43 million series A financing round in April of 2002, led by the Sprout Group, co-led by Tavistock Life Sciences and included CMEA Ventures, Lombard Odier Darier Hentsch & Cie, 5AM Ventures, Novartis Bioventure Fund, Aravis Ventures, Alejandro Zaffaroni
and the Singapore E.